Last reviewed · How we verify
Ravicti — Competitive Intelligence Brief
marketed
glycerol phenylbutyrate
Metabolic
Small molecule
Live · refreshed every 30 min
Target snapshot
Ravicti (GLYCEROL PHENYLBUTYRATE) — Horizon Therap Us. PAA, derived from glycerol phenylbutyrate, conjugates with glutamine to form PAGN, providing an alternate pathway for nitrogen excretion.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ravicti TARGET | GLYCEROL PHENYLBUTYRATE | Horizon Therap Us | marketed | glycerol phenylbutyrate | 2013-01-01 |
Recent regulatory actions (last 90 days)
- — Ravicti · FDA · approved · US · Horizon Therap Us
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (glycerol phenylbutyrate class)
- Horizon Therap Us · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ravicti CI watch — RSS
- Ravicti CI watch — Atom
- Ravicti CI watch — JSON
- Ravicti alone — RSS
- Whole glycerol phenylbutyrate class — RSS
Cite this brief
Drug Landscape (2026). Ravicti — Competitive Intelligence Brief. https://druglandscape.com/ci/glycerol-phenylbutyrate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab